Norma C. Gutiérrez

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

Laura Rosiñol, Albert Oriol, Ana Isabel Teruel et al. · Blood · 2012 · 485 citations · Full text

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

Bruno Paiva, María‐Belén Vídriales, Jorge Cerveró et al. · Blood · 2008 · 463 citations · Full text

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López et al. · The Lancet Oncology · 2010 · 459 citations

Hematological Malignancy, Elderly Patients, Medicine +7

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

María‐Victoria Mateos, JoséM. Hernández, M.B. Gómez Hernández et al. · Blood · 2006 · 388 citations · Full text

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

Jesús F. San Miguel, María‐Belén Vídriales, C López-Berges et al. · Blood · 2001 · 331 citations · Full text